Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14949540 | 0.88 | GAA (0.47) | GAATDP1SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL16405708 | 0.84 | SMN1; SMN2 (0.47) | GAATDP1SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL9492517 | 0.83 | GAA (0.55) | GAATDP1SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL12396072 | 0.82 | GAA (0.62) | GAATDP1SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL22481574 | 0.82 | ALDH1A1 (0.60) | GAATDP1SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL3221432 | 0.82 | GAA (0.53) | GAATDP1SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL3400610 | 0.81 | GAA (0.57) | GAATDP1SMN1; SMN2PKMKMT2A | |
| SCHEMBL1970601 | 0.81 | L3MBTL1 (0.56) | GAASMN1; SMN2ALDH1A1RAB9ALMNA | |
| SCHEMBL12436034 | 0.79 | ALDH1A1 (0.42) | GAASMN1; SMN2PKMALDH1A1MAPT | |
| SCHEMBL12991627 | 0.79 | GAA (0.59) | GAATDP1SMN1; SMN2PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | claimed |
| US-10426169-B2 | Heteroarylpiperidine and -piperazine derivatives as fungicides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-10-01 | — | — | US | disclosed |
| EP-2921485-B1 | ISOXAZOLE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2018-07-18 | — | — | EP | disclosed |
| US-20180103641-A1 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-04-19 | — | — | US | disclosed |
| US-20180103641-A1 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-04-19 | — | — | US | disclosed |
| EP-2921495-B1 | HETEROARYLPIPERIDINE AND HETEROARYLPIPERAZINE DERIVATIVES AS FUNGICIDES | BAYER IP GMBH (DE) | 2018-03-28 | — | — | EP | disclosed |
| EP-2921492-B1 | HETEROARYLPIPERIDINE AND HETEROARYLPIPERAZINE DERIVATIVES | BAYER IP GMBH (DE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2921493-B1 | HETEROARYLPIPERIDINE AND HETEROARYLPIPERAZINE DERIVATIVES | BAYER IP GMBH (DE) | 2017-08-16 | — | — | EP | disclosed |
| EP-2921491-B1 | INTERMEDIATES FOR THE PRODUCTION OF HETEROARYLPIPERIDINE AND - HETEROARYLPIPERAZINE DERIVATIVES AS FUNGICIDES | BAYER IP GMBH (DE) | 2017-08-16 | — | — | EP | disclosed |
| US-20160200720-A1 | HETEROARYLPIPERIDINE AND PIPERAZINE DERIVATIVES AS FUNGICIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-14 | — | — | US | disclosed |
| EP-2921492-A1 | HETEROARYLPIPERIDINE AND HETEROARYLPIPERAZINE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2015-09-23 | — | — | EP | disclosed |
| EP-2921484-A1 | OXAZOLE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2015-09-23 | — | — | EP | disclosed |
| EP-2921491-A1 | INTERMEDIATES FOR THE PRODUCTION OF HETEROARYLPIPERIDINE AND HETEROARYLPIPERAZINE DERIVATIVES AS FUNGICIDES | Bayer Intellectual Property GmbH (DE) | 2015-09-23 | — | — | EP | disclosed |
| EP-2921485-A1 | ISOXAZOLE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2015-09-23 | — | — | EP | disclosed |
| EP-2921493-A1 | HETEROARYLPIPERIDINE AND HETEROARYLPIPERAZINE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-20150024935-A1 | HETEROARYLPIPERIDINE AND PIPERAZINE DERIVATIVES AS FUNGICIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-20150024935-A1 | HETEROARYLPIPERIDINE AND PIPERAZINE DERIVATIVES AS FUNGICIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200720-A1 | HETEROARYLPIPERIDINE AND PIPERAZINE DERIVATIVES AS FUNGICIDES | RB1, RBX1, RRP12 | GAA 1939/4885TDP1 2070/4885SMN1; SMN2 3201/4885 |
| US-10426169-B2 | Heteroarylpiperidine and -piperazine derivatives as fungicides | RB1, RBX1, RRP12 | GAA 1717/4885TDP1 2080/4885SMN1; SMN2 3589/4885 |
| US-20180103641-A1 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES AS FUNGICIDES | RB1, RBX1, RRP12 | GAA 1717/4885TDP1 2080/4885SMN1; SMN2 3589/4885 |
| US-20150024935-A1 | HETEROARYLPIPERIDINE AND PIPERAZINE DERIVATIVES AS FUNGICIDES | RB1, RBX1, RRP12 | GAA 1939/4885TDP1 2070/4885SMN1; SMN2 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.